Isomorphic Labs
Funding History
| First External Investment Round · 03/2025 | $600M |
|---|---|
| Series B · 05/2026 | $2.1B |
About
Isomorphic Labs is an AI drug discovery company headquartered in London, with additional offices in Cambridge, Massachusetts and Lausanne, Switzerland. It was spun out of Google DeepMind in 2021 by DeepMind co-founder and CEO Demis Hassabis, who leads Isomorphic Labs as founder and CEO while continuing to lead DeepMind.
- CEO
- Demis Hassabis
- Headquarters
- London
- Founded
- 2021
- Website
- isomorphiclabs.com
Overview
Isomorphic Labs is a London-based AI drug discovery company spun out of Google DeepMind, incorporated in February 2021 and launched publicly in November 2021 by DeepMind co-founder and CEO Demis Hassabis, who serves as Isomorphic Labs' founder and CEO as well. The company builds on DeepMind's AlphaFold protein-structure technology to run an AI-first drug design engine, which it uses both for its own internal drug pipeline and through paid collaborations with large pharmaceutical companies.
Since January 2024 it has signed multi-target research partnerships with Eli Lilly, Novartis, and, as of January 2026, Johnson & Johnson's Janssen Biotech unit, together worth billions of dollars in potential upfront and milestone payments.
Isomorphic Labs remained wholly funded by parent company Alphabet until March 2025, when it closed its first external investment round, a $600 million raise led by Thrive Capital with GV and Alphabet also participating. It followed that with a $2.1 billion Series B round announced in May 2026, again led by Thrive Capital, joined by Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund; the company did not disclose an official valuation alongside either round. As of September 2026 Isomorphic Labs remains a private company and an Alphabet subsidiary, with no public listing.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.